Keratoconus is a progressive disease which results in the thinning of the cornea (the clear, front part of the eye). Consequently, the cornea assumes a more cone-like shape.
Patients with keratoconus often struggle with glare, ghost images, halos, double vision, and a host of other visual challenges. It is often discovered when their vision cannot be properly corrected with glasses.
A new FDA clinical trial led by Thomas Mauger, MD, called corneal crosslinking, studies the effect of Vitamin B2 eye drops and exposure to ultraviolet light on the progression of corneal thinning and visual acuity.
The goal is to evaluate the safety and effectiveness of corneal crosslinking for the treatment of keratoconus as well as corneal thinning following laser vision correction surgery (LASIK). Other investigators who are participating in the study are Andrew Hendershot MD, Rebecca Kuennen MD, and Richard Lembach, MD.